Stocktoria
Greenland Mines Ltd GRML
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2022-04-29
Greenland Mines Ltd financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| R&D expense | $634,187 | $0 | $0 | — |
| Operating income | -$7.1M | -$5.5M | -$631,322 | -$657,018 |
| Income tax | — | — | $690,572 | $322,025 |
| Net income | -$10.6M | -$6.2M | -$707,458 | $1.2M |
| EPS (diluted) | $-0.22 | $-0.32 | $-0.05 | — |
| Operating cash flow | -$5.9M | -$2.9M | -$446,916 | -$493,043 |
| Cash & equivalents | $7.2M | $63,741 | $2,808 | $340,962 |
| Total assets | $9.6M | $2.5M | $2.2M | $118.2M |
| Total liabilities | $129,764 | $1.3M | $1.6M | $4.9M |
| Shareholders' equity | $9.5M | $1.2M | -$442,701 | -$4.0M |
Source: SEC EDGAR filings · CIK 0001907223 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.